scholarly journals Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy

2016 ◽  
Vol 12 (6) ◽  
pp. 511-518 ◽  
Author(s):  
Maria E. Cabanillas ◽  
Mark Zafereo ◽  
G. Brandon Gunn ◽  
Renata Ferrarotto
Keyword(s):  
Targeted Therapy ◽  
Thyroid Carcinoma ◽  
Molecular Targeted Therapy ◽  
Standard Of Care ◽  
Anaplastic Thyroid Carcinoma ◽  
Novel Therapies ◽  
Current Standard ◽  
Major Barrier

Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity by which it grows has been a major barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, and few are cured; however, novel therapies and approaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.

Anaplastic thyroid carcinoma: The failure of conventional therapy but the real promise of targeted therapy

2015 ◽  
Author(s):  
Paul Lennon ◽  
Sandra Deady ◽  
Marie-Louise Healy ◽  
John Kinsella ◽  
Conrad Timon ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Thyroid Carcinoma ◽  
Conventional Therapy ◽  
Anaplastic Thyroid Carcinoma ◽  
The Real

scholarly journals Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma

2021 ◽  
Vol 14 (1) ◽  
pp. 51
Author(s):  
Brinda Balasubramanian ◽  
Simran Venkatraman ◽  
Kyaw Zwar Myint ◽  
Tavan Janvilisri ◽  
Kanokpan Wongprasert ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
Drug Development ◽  
Surgical Resection ◽  
Treatment Options ◽  
Standard Of Care ◽  
Time Data ◽  
Current Standard ◽  
Innovative Drug ◽  
Curative Intent

Cholangiocarcinoma (CCA), a group of malignancies that originate from the biliary tract, is associated with a high mortality rate and a concerning increase in worldwide incidence. In Thailand, where the incidence of CCA is the highest, the socioeconomic burden is severe. Yet, treatment options are limited, with surgical resection being the only form of treatment with curative intent. The current standard-of-care remains adjuvant and palliative chemotherapy which is ineffective in most patients. The overall survival rate is dismal, even after surgical resection and the tumor heterogeneity further complicates treatment. Together, this makes CCA a significant burden in Southeast Asia. For effective management of CCA, treatment must be tailored to each patient, individually, for which an assortment of targeted therapies must be available. Despite the increasing numbers of clinical studies in CCA, targeted therapy drugs rarely get approved for clinical use. In this review, we discuss the shortcomings of the conventional clinical trial process and propose the implementation of a novel concept, co-clinical trials to expedite drug development for CCA patients. In co-clinical trials, the preclinical studies and clinical trials are conducted simultaneously, thus enabling real-time data integration to accurately stratify and customize treatment for patients, individually. Hence, co-clinical trials are expected to improve the outcomes of clinical trials and consequently, encourage the approval of targeted therapy drugs. The increased availability of targeted therapy drugs for treatment is expected to facilitate the application of precision medicine in CCA.

Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy

Head & Neck ◽  
2016 ◽  
Vol 38 (S1) ◽  
pp. E1122-E1129 ◽  
Author(s):  
Paul Lennon ◽  
Sandra Deady ◽  
Maire L. Healy ◽  
Mary Toner ◽  
John Kinsella ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Thyroid Carcinoma ◽  
Conventional Therapy ◽  
Anaplastic Thyroid Carcinoma

scholarly journals Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review

2021 ◽  
Vol 11 ◽  
Author(s):  
Lennox Chitsike ◽  
Penelope J. Duerksen-Hughes
Keyword(s):  
Targeted Therapy ◽  
Targeted Therapies ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Therapeutic Index ◽  
Clinical Validation ◽  
Current Standard ◽  
Ongoing Research ◽  
Molecular Features

The treatment landscape of locally advanced HPV-oropharyngeal squamous cell carcinoma (OPSCC) is undergoing transformation. This is because the high cures rates observed in OPSCC are paired with severe treatment-related, long-term toxicities. These significant adverse effects have led some to conclude that the current standard of care is over-treating patients, and that de-intensifying the regimens may achieve comparable survival outcomes with lower toxicities. Consequently, several de-escalation approaches involving locally advanced OPSCC are underway. These include the reduction of dosage and volume of intensive cytotoxic regimens, as well as elimination of invasive surgical procedures. Such de-intensifying treatments have the potential to achieve efficacy and concurrently alleviate morbidity. Targeted therapies, given their overall safer toxicity profiles, also make excellent candidates for de-escalation, either alone or alongside standard treatments. However, their role in these endeavors is currently limited, because few targeted therapies are currently in clinical use for head and neck cancers. Unfortunately, cetuximab, the only FDA-approved targeted therapy, has shown inferior outcomes when paired with radiation as compared to cisplatin, the standard radio-sensitizer, in recent de-escalation trials. These findings indicate the need for a better understanding of OPSCC biology in the design of rational therapeutic strategies and the development of novel, OPSCC-targeted therapies that are safe and can improve the therapeutic index of standard therapies. In this review, we summarize ongoing research on mechanism-based inhibitors in OPSCC, beginning with the salient molecular features that modulate tumorigenic processes and response, then exploring pharmacological inhibition and pre-clinical validation studies of candidate targeted agents, and finally, summarizing the progression of those candidates in the clinic.

Abstract #1003565: Opportunity and Challenges of Using Novel Therapies in a Case of Anaplastic Thyroid Carcinoma

2021 ◽  
Vol 27 (6) ◽  
pp. S167-S168
Author(s):  
Malek Mushref ◽  
Matthew Bridges ◽  
Denise Carneiro-Pla ◽  
Jyotika Fernandes ◽  
John Kaczmar ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Novel Therapies

Real-world utilization of multiple myeloma treatments in the era of novel therapies: What is the current standard of care?

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e20019-e20019
Author(s):  
David Singer ◽  
Ellen Thiel ◽  
Debra E. Irwin ◽  
Meghan Moynihan ◽  
Caroline McKay ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Standard Of Care ◽  
Novel Therapies ◽  
Current Standard

scholarly journals Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

2021 ◽  
Vol 22 (19) ◽  
pp. 10232
Author(s):  
Paul Lee ◽  
Rita Yim ◽  
Yammy Yung ◽  
Hiu-Tung Chu ◽  
Pui-Kwan Yip ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Molecular Targeted Therapy ◽  
Somatic Mutations ◽  
Standard Of Care ◽  
Hypomethylating Agents ◽  
Mechanisms Of Resistance ◽  
Leukemic Transformation ◽  
Combinational Therapies

Myelodysplastic syndrome (MDS) is a heterogeneous, clonal hematological disorder characterized by ineffective hematopoiesis, cytopenia, morphologic dysplasia, and predisposition to acute myeloid leukemia (AML). Stem cell genomic instability, microenvironmental aberrations, and somatic mutations contribute to leukemic transformation. The hypomethylating agents (HMAs), azacitidine and decitabine are the standard of care for patients with higher-risk MDS. Although these agents induce responses in up to 40–60% of patients, primary or secondary drug resistance is relatively common. To improve the treatment outcome, combinational therapies comprising HMA with targeted therapy or immunotherapy are being evaluated and are under continuous development. This review provides a comprehensive update of the molecular pathogenesis and immune-dysregulations involved in MDS, mechanisms of resistance to HMA, and strategies to overcome HMA resistance.

scholarly journals Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma

Thyroid ◽  
2018 ◽  
Vol 28 (1) ◽  
pp. 79-87 ◽  
Author(s):  
Priyanka C. Iyer ◽  
Ramona Dadu ◽  
Renata Ferrarotto ◽  
Naifa L. Busaidy ◽  
Mouhammed A. Habra ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Thyroid Carcinoma ◽  
Real World ◽  
Anaplastic Thyroid Carcinoma

scholarly journals Contemporary treatment of metastatic renal cell carcinoma

2016 ◽  
Author(s):  
Igor Stukalin ◽  
Nimira Alimohamed ◽  
Daniel Y.C. Heng
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Growth Factor Receptor ◽  
Standard Of Care ◽  
Current Standard ◽  
Inhibition Of Angiogenesis

The introduction of targeted therapy has revolutionized the treatment of patients with metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR). Over the past few years, research exploring novel targeted agents has blossomed, leading to the approval of various targeted therapies. Furthermore, results from the CheckMate025 and the METEOR trials have brought about two additional novel options: the programmed cell death 1 (PD-1) checkpoint inhibitor nivolumab and the MET/VEGFR/AXL inhibitor cabozantinib, respectively. With the variety of therapeutic agents available for treatment of mRCC, research examining appropriate sequencing and combinations of the drugs is ongoing. This review discusses the role of prognostic criteria, such as those from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. It also covers the current standard of treatment for mRCC with targeted therapy in first-, second-, and thirdline setting. Additionally, the novel mechanism of action of nivolumab and cabozantinib, therapeutic sequencing and ongoing clinical trials are discussed.

Sign in / Sign up

Export Citation Format

Share Document